Literature DB >> 6191008

HLA antigens and progression of multiple sclerosis. Part II.

L Dejaegher, M de Bruyere, P Ketelaer, H Carton.   

Abstract

The HLA-A, -B, -C and -D were determined in 200 multiple sclerosis (MS) patients, 64 of whom underwent a CSF examination. Their frequencies were correlated with the rate of disease progression and with factors thought to influence disease progression, including onset age, type of clinical course and intrathecal IgG synthesis. No correlation was found between HLA haplotypes and progression rate or type of disease course. Patients starting MS after age 31 years carried the DR2 determinant more frequently (P = 0.016) than patients with onset before this median age. Although the greatest proportion of patients with an IgG index greater than 1.5 or more than 15 oligoclonal bands in their CSF were DR2 carriers, no statistical difference was found in the intrathecal IgG synthesis of HLA-DR2 (+) and (-) patients.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6191008     DOI: 10.1007/bf00313740

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  10 in total

1.  HLA antigens in multiple sclerosis.

Authors:  E Thorsby; A Helgesen; B G Solheim; B Vandvik
Journal:  J Neurol Sci       Date:  1977-06       Impact factor: 3.181

2.  HLA in multiple sclerosis. Relationship to measles antibody, mitogen responsiveness and clinical course.

Authors:  D W Paty; J B Dossetor; C R Stiller; H K Cousin; L Marchuk; J Furesz; D W Boucher
Journal:  J Neurol Sci       Date:  1977-07       Impact factor: 3.181

3.  A double-blind trial of transfer factor vs placebo in multiple sclerosis patients.

Authors:  R C Collins; L R Espinoza; C R Plank; G C Ebers; R A Rosenberg; J B Zabriskie
Journal:  Clin Exp Immunol       Date:  1978-07       Impact factor: 4.330

4.  Letter: HL-A antigens in multiple sclerosis.

Authors:  J Bertrams; P G Höher; E Kuwert
Journal:  Lancet       Date:  1974-06-22       Impact factor: 79.321

5.  Histocompatibility determinants in multiple sclerosis, with special reference to clinical course.

Authors:  C Jersild; T Fog; G S Hansen; M Thomsen; A Svejgaard; B Dupont
Journal:  Lancet       Date:  1973-12-01       Impact factor: 79.321

6.  Simultaneous detection of two cell populations by two-colour fluorescence and application to the recognition of B-cell determinants.

Authors:  J J van Rood; A van Leeuwen; J S Ploem
Journal:  Nature       Date:  1976-08-26       Impact factor: 49.962

7.  HLA profiles in multiple sclerosis suggest two forms of disease and the existence of protective haplotypes.

Authors:  M Madigand; J J Oger; R Fauchet; O Sabouraud; B Genetet
Journal:  J Neurol Sci       Date:  1982-03       Impact factor: 3.181

8.  [Histocompatibility patterns in multiple sclerosis. Findings of an epidemiological study (author's transl)].

Authors:  S Poser; G Ritter; H J Bauer; E K Kuwert; P G Höher; H Grosse-Wilde; E Hierholzer
Journal:  Nervenarzt       Date:  1981-06       Impact factor: 1.214

9.  Genetic basis of multiple sclerosis: HLA antigens, disease progression, and oligoclonal IgG in CSF.

Authors:  L Stendahl-Brodin; H Link; E Möller; E Norrby
Journal:  Acta Neurol Scand       Date:  1979-06       Impact factor: 3.209

10.  HLA-typing and lymphocyte population studies in patients with multiple sclerosis.

Authors:  P Reekers; O R Hommes; J Creemers-Molenaar; J Wijnings; V A Kunst; J J Van Rood
Journal:  J Neurol Sci       Date:  1977-08       Impact factor: 3.181

  10 in total
  3 in total

1.  HLA and prognosis in multiple sclerosis.

Authors:  B Runmarker; T Martinsson; J Wahlström; O Andersen
Journal:  J Neurol       Date:  1994-05       Impact factor: 4.849

2.  HLA antigens in Italian multiple sclerosis patients.

Authors:  L La Mantia; M T Illeni; C Milanese; A Salmaggi; M Eoli; G Pellegris; A Nespolo
Journal:  Ital J Neurol Sci       Date:  1991-02

3.  Histocompatibility antigens in multiple sclerosis patients participating in a multicentre trial of azathioprine. British & Dutch Multiple Sclerosis Azathioprine Trial Group.

Authors: 
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-03       Impact factor: 10.154

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.